Genmab

Genmab’s latest quarterly results reveal a resilient biotech firm on track to expand its antibody cancer therapies, showcasing solid growth and future potential.

Genmab’s 2025 stock outlook: strong market cap, bullish price target, and resilient biotech growth despite no new announcements.

Genmab A/S, a Danish biotechnology firm, continues to demonstrate momentum in the antibody-therapeutics market, driven by positive trial data and strategic growth initiatives, despite a recent dip in share price due to market volatility.